Tideglusib, an inhibitor of the kinase GSK3β

Mike Snape, AMO Pharma

30th October 2016

AMO Pharma is developing Tideglusib, a selective inhibitor of GSK3β, as a potential therapy for myotonic dystrophy type 1 (DM1). The request for TACT guidance was focused on a planned Phase II/III study in paediatric congenital DM1.

TACT believes AMO’s application for review and the subsequent report, represents an opportunity to generate robust, conclusive preclinical data before proceeding to a phase III clinical trial. Additional preclinical studies have already commenced, with this objective in mind. This can provide key de-risking for the company and also generate support from the clinician and patient/parent community. TACT’s full report includes key recommendations for the design of preclinical studies as well as for the proposed paediatric clinical trial.

To request a full copy of the report please contact the applicant Mike Snape: mike.snape@amo-pharma.com

12 Apr 2017